PLUS THERAPEUTICS INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
PLUS THERAPEUTICS INC. - More news...
PLUS THERAPEUTICS INC. - More news...
- Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference
- Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer
- Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
- Plus Therapeutics Announces New Employment Inducement Grants
- Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024
- Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial
- Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
- Plus Therapeutics Announces Private Placement Financing of up to $18 Million
- Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
- Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team
- Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
- Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
- Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases
- Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
- Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024
- Plus Updates Financial and Cash Guidance for 2024
- Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses
- Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe
- Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
- Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023
- Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases
- Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases
- Plus Therapeutics Announces Share Repurchase Program
- Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
- Plus Therapeutics to Present at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
- Plus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on October 31, 2023
- Plus Therapeutics Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium (¹⁸⁶Re) Obisbemeda in Leptomeningeal Metastases
- Plus Therapeutics to Participate in the Jones Trading Healthcare Summit and ThinkEquity Conference in October
- Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference
